Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neovascularization

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    171 result(s) found for: Neovascularization. Displaying page 3 of 9.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2012-005417-38 Sponsor Protocol Number: CRFB002G2301 Start Date*: 2013-07-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to ...
    Medical condition: Visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10060837 Choroidal neovascularization LLT
    17.0 10015919 - Eye disorders 10047571 Visual impairment PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) IT (Completed) LV (Completed) PT (Completed) HU (Completed) CZ (Completed) ES (Completed) LT (Completed) BE (Completed) GR (Completed) DK (Completed) DE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-005542-35 Sponsor Protocol Number: CRFB002DDE21 Start Date*: 2012-05-08
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Multicenter randomized open-label three-arms controlled 12 months clinical proof of concept study to evaluate efficacy and safety of Ranibizumab alone or in combination with laser photocoagulation ...
    Medical condition: Proliferative diabetic retinopathy
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10036857 Proliferative diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001600-23 Sponsor Protocol Number: HLS02/2008 Start Date*: 2010-01-08
    Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
    Full Title: Prospective, randomized, single masked pilot study on the variation of choroidal blood flow analyzed through the HRA dynamic angiography in patients treated with intravitreal injection of Selecti...
    Medical condition: Choroidal neovascularization in patients with age-related macular degeneration.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005157-33 Sponsor Protocol Number: 1 Start Date*: 2008-05-14
    Sponsor Name:Ludwig Boltzmann Institut für Retinologie und biomikroskopische Laserchirurgie
    Full Title: A randomized observer and subject masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration Multicenter...
    Medical condition: Subjects of either gender, aged> 50 years, presenting with subfoveal choroidal neovascularization due to age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020441-27 Sponsor Protocol Number: CORaLa Start Date*: 2011-02-23
    Sponsor Name:University of Leipzig Ritterstr. 26, 04109 Leipzig
    Full Title: Ranibizumab combined with selective peripheral laser photocoagulation for treatment of central retinal vein occlusion A randomized, controlled interventional phase 2b (proof of concept) study of ...
    Medical condition: macular edema secondary to non-ischemic central retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10054467 Macular edema LLT
    14.0 10015919 - Eye disorders 10007972 Central retinal vein occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004296-11 Sponsor Protocol Number: EOP 1010B Start Date*: 2005-07-12
    Sponsor Name:(OSI) Eyetech Pharamceuticals Inc
    Full Title: An open label, non-comparative protocol for the use of pegaptanib sodium injection every 6 weeks in patients with exudative age-related macular degeneration (AMD).
    Medical condition: Exudative Age Related Macular Degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    8 10025411 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PT (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003017-18 Sponsor Protocol Number: OPH1003 Start Date*: 2013-11-21
    Sponsor Name:OPHTHOTECH CORPORATION
    Full Title: A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (anti PDGF-b pegylated aptamer) administered in combination w...
    Medical condition: Subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
    Disease: Version SOC Term Classification Code Term Level
    18.1 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    18.1 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Completed) ES (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002997-33 Sponsor Protocol Number: OPH1002A Start Date*: 2014-02-11
    Sponsor Name:OPHTHOTECH CORPORATION
    Full Title: A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (anti PDGF-b pegylated aptamer) administered in combination w...
    Medical condition: Subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10071129 Neovascular age-related macular degeneration LLT
    16.1 100000004853 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) LV (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) EE (Prematurely Ended) SK (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014409-15 Sponsor Protocol Number: CRFB002DPT04T Start Date*: 2010-01-08
    Sponsor Name:AIBILI - Association for Innovation and Biomedical Research on Light and Image
    Full Title: Prospective, randomized, multicenter, open label phase II study to access efficacy and safety of Lucentis monotherapy (ranibizumab 0.5 mg intravitreal injections) compared with Lucentis plus panret...
    Medical condition: Proliferative Diabetic Retinopathy.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036857 Proliferative diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005464-14 Sponsor Protocol Number: LucNVG0108 Start Date*: 2009-03-30
    Sponsor Name:Prof. Salvatore Grisanti
    Full Title: An open label, prospective, monocenter, prove of concept study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections as adjuvant for patients with rube...
    Medical condition: Rubeosis and Neovascular Glaucoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039291 Rubeosis iridis LLT
    9.1 10062891 Neovascular glaucoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003816-19 Sponsor Protocol Number: V4061 Start Date*: 2016-10-14
    Sponsor Name:ForSight VISION4, Inc
    Full Title: A Controlled Safety and Preliminary Efficacy Study of the V406 Port Delivery System in the Treatment of Choroidal Neovascularization Due toAge-Related Macular Degeneration
    Medical condition: Patients of either sex, 50 years of age or older, with a diagnosis of Choroidal Neovascularization CNV due to Age-Related Macular Degeneration AMD in the study eye
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-016158-42 Sponsor Protocol Number: IT-04-1-8-09 Start Date*: 2009-12-23
    Sponsor Name:U.L.S.S. 16
    Full Title: Efficacy of intravitreal bevacizumab for exudative age-related macular degeneration.
    Medical condition: Exudative age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    12.1 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001856-19 Sponsor Protocol Number: MRVT-920101-OPH005 Start Date*: 2005-10-24
    Sponsor Name:Miravant Pharmaceuticals, Inc.
    Full Title: A Phase III Randomized, Multicenter, Multinational, Double-Masked, Placebo-Controlled Study of Photrex™ (Rostaporfin) Photodynamic Therapy in the Treatment of Classic and Occult Subfoveal Choroidal...
    Medical condition: classic and occult subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-016760-36 Sponsor Protocol Number: CC-02-2009 Start Date*: 2010-02-05
    Sponsor Name:AIBILI
    Full Title: Prospective, randomized, open label phase II study to assess efficacy and safety of Macugen® (pegaptanib 0.3 mg intravitreal injections) plus panretinal photocoagulation (PRP) and PRP (monotherapy)...
    Medical condition: Proliferative Diabetic Retinopathy.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036857 Proliferative diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001200-36 Sponsor Protocol Number: AVA001 Start Date*: 2006-09-18
    Sponsor Name:St. Eriks Eye Hospital [...]
    1. St. Eriks Eye Hospital
    2.
    3. St. Eriks Eye Hospital
    4.
    Full Title: A prospective, randomized, masked and controlled trial of intravitreal bevacizumab (Avastin) versus verteporfin photodynamic therapy (PDT) in patients with neovascular age-related macular degenera...
    Medical condition: Age-related macular degeneration (AMD) is the leading cause of visual impairment and social blindness in people 60 years or older. Approximately 75% of patients with severe visual loss exhibit ne...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005263-33 Sponsor Protocol Number: AUG-201202-EyNeP Start Date*: 2015-04-29
    Sponsor Name:Medizinische Fakultät der Universität Bonn
    Full Title: Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum
    Medical condition: Choroidal neovascularizations and fibrovascular proliferations in patients with Pseudoxanthoma elasticum
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10037150 Pseudoxanthoma elasticum PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001727-19 Sponsor Protocol Number: 45/2006/U/Sper Start Date*: 2006-10-03
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Triamcinolone Acetonide Intravitreal Injection for the treatment for exudative maculopathy
    Medical condition: exudative maculopathy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10038862 Retinal exudates LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000487-11 Sponsor Protocol Number: CRFB002D2201 Start Date*: 2005-09-30
    Sponsor Name:Novartis Pharma Service AG
    Full Title: A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the...
    Medical condition: Male and female patients >18 years of age with either type 1 or type 2 diabetes mellitus with stable HbA1c levels between 6.5 and 10% and diabetic macular edema with center involvement in at least ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) GB (Completed) AT (Completed) ES (Completed) IT (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000294-33 Sponsor Protocol Number: LX201-02 Start Date*: 2007-07-27
    Sponsor Name:Lux Biosciences, Inc.
    Full Title: A MULTI-CENTER, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL-GROUP, DOSE-RANGING STUDY TO ASSESS THE EFFICACY AND SAFETY OF LX201 IMPLANTATION FOR THE PREVENTION OF CORNEAL ALLOGRAFT REJECTION EPISODES...
    Medical condition: Patient after penetrating keratoplasty who have experienced one or more rejection episodes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011017 Corneal graft rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003132-21 Sponsor Protocol Number: EURIVAT1 Start Date*: 2005-09-28
    Sponsor Name:Dept. of Ophthalmology, Medical University of Vienna
    Full Title: European Intravitreal Avastin® Trial 1
    Medical condition: Neovascular / exudative age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 09 17:27:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA